Status:
COMPLETED
Neurocognition and Work Productivity in Major Depressive Disorder (MDD)
Lead Sponsor:
University of British Columbia
Collaborating Sponsors:
Pfizer
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
19-55 years
Phase:
NA
Brief Summary
This study will investigate the relationships between subjective cognitive complaints, neurocognitive deficits, and work productivity in participants with Major Depressive Disorder (MDD), before and a...
Eligibility Criteria
Inclusion
- Clinical diagnosis of Major Depressive Disorder as per DSM-IV-TR
- Current employment of at least 15 hours per week
- Baseline score of 23 or greater on the Montgomery-Asberg Depression Rating Scale, indicating at least moderately severe depression
- Baseline score of 6 or greater on the British Columbia Cognitive Complaints Inventory, indicating at least moderate subjective cognitive complaints
- Competency to give informed consent
Exclusion
- Current receipt of short-term or long-term disability benefits from employer
- Serious suicidal risks as judged by the investigators
- Other DSM-IV-TR diagnoses:
- organic mental disorders
- active substance abuse/dependence, including alcohol
- schizophrenia, paranoid or delusional disorders, or other psychotic disorders
- (as primary diagnosis:) panic disorder, generalized anxiety disorder, obsessive-compulsive disorder, or post-traumatic stress disorder
- bipolar disorder
- bulimia nervosa or anorexia nervosa
- Serious illness that is not stabilized, including cardiac, hepatic, renal, respiratory, endocrinologic, neurologic, or hematologic disease
- Regular/current use of other psychotropic drugs and/or herbaceuticals
- Use of fluoxetine within 5 weeks of Visit 1, monoamine oxidase inhibitors within 14 days of Visit 1, and other antidepressants within 7 days of Visit 1 (all to ensure adequate drug washouts prior to neurocognitive assessment)
- Previous treatment with desvenlafaxine
- Treatment-resistance in the current episode, as defined by failure (i.e., lack of clinically significant response) of 2 or more antidepressants given at therapeutic doses for at least 6 weeks
- Any history of treatment with electroconvulsive therapy
- Initiation of formal psychotherapy (e.g., cognitive-behavioural therapy or interpersonal psychotherapy) with 2 months of Visit 1, or plans to start such psychotherapy during this study
- Current use of any other form of treatment for depression
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT01468610
Start Date
January 1 2012
End Date
December 1 2014
Last Update
April 10 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of British Columbia, Department of Psychiatry
Vancouver, British Columbia, Canada, V6T 2A1